

In the Claims:

Please cancel claims 32<sup>✓</sup> and 43<sup>✓</sup>.

Please amend claims 33 and 44 to read as follows:

C2  
SUB 2  
33. (Twice Amended) The method of claim 53, wherein at least one of the oligonucleotide primers comprises at least about 10 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NOS: 55, 56, 59-65 and 67.

C3  
SUB 3  
44. (Twice Amended) The method of claim 54 wherein the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NOS: 55, 56, 59-65 and 67.

Please add new claim 53 and 54 to read as follows:

C4  
SUB 4  
53. (New) A method for detecting breast cancer in a patient comprising:

(a) contacting a biological sample from a patient with at least two oligonucleotide primers in a polymerase chain reaction, wherein at least one of the oligonucleotides is specific for a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NO: 55, 56, 59-65 and 67; and complements of said nucleotide sequences; and

(b) detecting in the sample a polynucleotide sequence that amplifies in the presence of the oligonucleotide primers, thereby detecting breast cancer.

54. (New) A method for detecting breast cancer in a patient, comprising:

(a) obtaining a biological sample from the patient;

(b) contacting the biological sample with an oligonucleotide probe specific for a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NOS: 55, 56, 59-65 and 67, complements of said nucleotide sequences and sequences that hybridize to a sequence of SEQ ID NO: 55, 56, 59-65 and 67 under moderately stringent conditions; and